Financials Astra Industrial Group Company

Equities

1212

SA11RGL0IU14

Pharmaceuticals

End-of-day quote Saudi Arabian S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
173.6 ^SAR	+2.12%		-2.36%	+30.33%

Mar. 18	Astra Industrial Group Company(SASE:1212) added to FTSE All-World Index	CI
Mar. 04	Astra Industrial Group Company Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Valuation

Fiscal Period: December	2019	2020	2022	2023	2024	2025
Capitalization ¹	1,230	2,056	4,136	10,656	14,160	-
Enterprise Value (EV) ¹	2,165	2,756	4,136	10,656	14,160	14,160
P/E ratio	41.6 x	17.8 x	8.72 x	-	26.9 x	22.4 x
Yield	-	-	-	-	1.81%	2.03%
Capitalization / Revenue	0.66 x	1 x	-	3.73 x	4.4 x	3.94 x
EV / Revenue	0.66 x	1 x	-	3.73 x	4.4 x	3.94 x
EV / EBITDA	4.08 x	6.81 x	-	17.1 x	21.4 x	18.8 x
EV / FCF	-	-	-	17,972,304 x	-	-
FCF Yield	-	-	-	0%	-	-
Price to Book	1.01 x	1.55 x	-	-	-	-
Nbr of stocks (in thousands)	80,000	80,000	80,000	80,000	80,000	-
Reference price ²	15.38	25.70	51.70	133.2	177.0	177.0
Announcement Date	3/16/20	3/14/21	3/9/23	2/28/24	-	-

¹SAR in Million²SAR

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2019	2020	2022	2023	2024	2025
Net sales ¹	1,867	2,048	-	2,859	3,216	3,593
EBITDA ¹	301.5	302.1	-	621.7	662	754
EBIT	219.1	212.4	-	531.3	-	-
Operating Margin	11.73%	10.37%	-	18.59%	-	-
Earnings before Tax (EBT)	7.438	144.1	-	-	-	-
Net income ¹	29.7	115.4	474.3	475.3	527	634
Net margin	1.59%	5.64%	-	16.63%	16.39%	17.65%
EPS ²	0.3700	1.440	5.930	-	6.575	7.900
Free Cash Flow	-	-	-	592.9	-	-
FCF margin	-	-	-	20.74%	-	-
FCF Conversion (EBITDA)	-	-	-	95.37%	-	-
FCF Conversion (Net income)	-	-	-	124.74%	-	-
Dividend per Share ²	-	-	-	-	3.200	3.600
Announcement Date	3/16/20	3/14/21	3/9/23	2/28/24	-	-

¹SAR in Million²SAR

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1
Net sales ¹	748.3	667	653.5	789.7	824.5
EBITDA	-	-	-	-	-
EBIT	-	-	-	-	-
Operating Margin	-	-	-	-	-
Earnings before Tax (EBT)	-	-	-	-	-
Net income ¹	122.9	-	-	-	144.5
Net margin	16.42%	-	-	-	17.53%
EPS	-	-	-	-	-
Dividend per Share	-	-	-	-	-
Announcement Date	5/23/23	8/10/23	11/8/23	2/28/24	-

¹SAR in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2019	2020	2022	2023	2024	2025
Net Debt	935	700	-	-	-	-
Net Cash position	-	-	-	-	-	-
Leverage (Debt/EBITDA)	3.1 x	2.316 x	-	-	-	-
Free Cash Flow	-	-	-	593	-	-
ROE (net income / shareholders' equity)	2.61%	9.09%	-	23.9%	23%	22%
ROA (Net income/ Total Assets)	-	-	-	12.2%	-	-
Assets ¹	-	-	-	3,899	-	-
Book Value Per Share	15.20	16.60	-	-	-	-
Cash Flow per Share	4.680	3.400	-	-	-	-
Capex	36.9	62.4	-	88.1	-	-
Capex / Sales	1.98%	3.05%	-	3.08%	-	-
Announcement Date	3/16/20	3/14/21	3/9/23	2/28/24	-	-

¹SAR in Million

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Astra Industrial Group Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

177 SAR

Average target price

142.8 SAR

Spread / Average Target

-19.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ASTRA INDUSTRIAL GROUP COMPANY	+30.33%	3.78B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.34%	43.18B
OTSUKA HOLDINGS CO., LTD.	+20.67%	22.59B
SANDOZ GROUP AG	+15.26%	14.56B
ZYDUS LIFESCIENCES LIMITED	+40.95%	11.5B
ONO PHARMACEUTICAL CO., LTD.	-8.37%	6.93B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+10.21%	5.36B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-2.27%	4.81B

Generic Pharmaceuticals